N-(2,2-dimethylpropyl)pyridin-3-amine | 1250946-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(2,2-dimethylpropyl)pyridin-3-amine
• CAS: 1250946-71-4
• 化学式: C₁₀H₁₆N₂
• mdl: MFCD14625008
• 分子量: 164.25
• InChiKey: GNYFTORFAKIQDR-UHFFFAOYSA-N

物化性质

• 沸点：
  265.5±13.0 °C(Predicted)
• 密度：
  0.976±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Pyrrolotriazine Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
  申请人：Dixon A. Julie

  公开号：US20070208013A1

  公开（公告）日：2007-09-06

  This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

  本发明涉及新型吡唑三嗪化合物，含有这些化合物的药物组合物以及将这些化合物和组合物用于预防和/或治疗与血管生成相关的过度增殖性疾病的用途。
• PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
  申请人：Dixon Julie A.

  公开号：US20100075958A1

  公开（公告）日：2010-03-25

  This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

  本发明涉及吡咯烷三嗪化合物，含有这种化合物的制药组合物以及这些化合物和组合物在预防和/或治疗与血管生成相关的高增殖性疾病和疾病方面的使用。
• Benzimidazole derivatives
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10752611B2

  公开（公告）日：2020-08-25

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： 它们能抑制含 RNA 的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物可干扰丙型肝炎病毒的生命周期，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给丙型肝炎病毒感染者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者感染 HCV 的方法。
• Antimicrobial compounds and methods of making and using the same
  申请人：BIOVERSYS AG

  公开号：US10947237B2

  公开（公告）日：2021-03-16

  The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals.

  本公开内容一般涉及抗微生物化合物领域及其制造和使用方法。这些化合物可用于治疗、预防、降低微生物感染的风险并延缓人类和动物微生物感染的发生。
• Antimicrobial Compounds And Methods Of Making And Using The Same
  申请人：Melinta Therapeutics, Inc.

  公开号：US20180065966A1

  公开（公告）日：2018-03-08

  The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals.